Trial Profile
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Phenformin (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 08 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology